Efficacy and Safety of Fixed-Dose Oral Sildenafil in the Treatment of Sexual Dysfunction in Depressed Patients with Idiopathic Parkinson's Disease

Raffaele, R; Vecchio, Ignazio; Giammusso, Bruno; Morgia, Giuseppe; Brunetto, Maurizia Rossana; Rampello, Liborio

doi:10.1016/s0302-2838(02)00054-4

Cited by 70 publications

(33 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The most common AEs seen were typical of PDE5 inhibitors (for example headache, hot flashes) and were of mild-to-moderate in nature. The AE profiles are similar to Raffaele et al 9 in spite of use of larger dose in this study. We could not fully explain this issue.…”

Section: Discussionsupporting

confidence: 89%

“…The reported improvement rate in EF was 84.4%. 9 The overall success rate with 100 mg sildenafil in our study was 65%. The overall positive response rate to sildenafil in the general population is between 65 and 75%.…”

Section: Discussionmentioning

confidence: 48%

“…9 The cited open-label study suffered from small sample size. In addition, all of the Figure 3 The percentage change from baseline in International Index of Erectile Function (IIEF) domains at the end of the study.…”

Section: Discussionmentioning

confidence: 99%

“…Although sildenafil is effective for treating ED in men with various comorbid conditions, little is known about the effect of sildenafil on erectile function (EF) in men with PD. In the study by Raffaele et al, 9 33 depressed men with PD and ED received 50 mg of sildenafil 1 h before sexual activity. At the end of the study, 84.8% of patients reported improved erection.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Safety and efficacy of sildenafil citrate in the treatment of Parkinson-emergent erectile dysfunction: a double-blind, placebo-controlled, randomized study

Safarinejad¹,

Taghva

Shekarchi

et al. 2010

Int J Impot Res

View full text Add to dashboard Cite

Parkinson's disease (PD) is one of the most commonly occurring neurodegenerative disorders, with lifetime incidence between 1 and 2% among people older than 65 years. ED is one of the more disabling and poorly addressed aspects of PD. The purpose of this study was to assess the efficacy and safety of sildenafil citrate in Parkinson-emergent ED. Sexual function of participants was assessed using responses to the 15-question International Index of Erectile Function (IIEF), Sexual Encounter Profile (SEP) diary questions 2 and 3, Erectile Dysfunction Inventory of Treatment Satisfaction (EDITS) questionnaire and a Global Efficacy Question 'Has the treatment you have been taking over the study period improved your erections?' This randomized, double-blind, placebocontrolled study, comprised a screening period of at least 1 month, a placebo-lead in period of 1 week and treatment period. Two hundred thirty-six patients entered the trial. These patients had mild-to-moderate PD (stages I-III Hoehn-Yahr) and were experiencing Parkinson-emergent neurogenic ED. They were randomized to receive 100 mg sildenafil on demand 1 h before sexual activity (group 1, n ¼ 118), or similar regimen of placebo (group 2, n ¼ 118). Patients were instructed to use at least 24 doses/attempts at home. At the end of the trial, differences between sildenafil and placebo groups were significant for the IIEF erectile function (EF) score (22.6 ± 4.6 vs 14.8 ± 4.2, P ¼ 0.01), for percent Global Efficacy Question 'Yes' responses (68.1±4.6 vs 12.2±3.2, P ¼ 0.001), for SEP2 'Yes' responses (68.1±4.2 vs 32.5±2.2, P ¼ 0.003), for SEP3 'Yes' responses (75.9±5.4 vs 33.5 ± 4.4, P ¼ 0.004) and for mean EDITS score (69.8 ± 4.2 vs 13.0 ± 2.7, P ¼ 0.004). A normal EF domain score (X26) at end point was achieved by 56.9 and 8.7% of the patients in the sildenafil and placebo groups, respectively (P ¼ 0.001). Sildenafil can be considered as an effective treatment in patients with Parkinson-emergent ED.

show abstract

Section: Discussionsupporting

confidence: 89%

Section: Discussionmentioning

confidence: 48%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Safety and efficacy of sildenafil citrate in the treatment of Parkinson-emergent erectile dysfunction: a double-blind, placebo-controlled, randomized study

Safarinejad¹,

Taghva

Shekarchi

et al. 2010

Int J Impot Res

View full text Add to dashboard Cite

show abstract

“…32 Sildenafil is an effective treatment for ED in men with several neurological disorders, also PD. 33,34 Its efficacy in PD patients with ED and depression was reported to be 85%. 33 Symptoms of Parkinson's disease and decreased libido in the non-depressed patient can be treated in different ways.…”

Section: Treatments Of Sexual Disorders Associated To Pdmentioning

confidence: 99%

Male Sexual Disorders in Patients with Parkinson Disease: Treatment with Natural Remedies

Mireille¹

2017

ATROA

View full text Add to dashboard Cite

In patients with PD, sexual disorders usually begin after the onset AbstractParkinson's disease (PD) is a neurodegenerative disorder caused by a progressive deterioration of midbrain dopamine neurons in the substantia nigra. The incidence of PD in male is higher than that in women, but psychological symptoms are as varied as the motor symptoms in both gender. Psychological symptoms encompass a decrease in sexual desire with a long list of thymic, cognitive, behavioral, and neuropsychiatric complications. Their origin can be attributed to the natural course of the disease, side effects of treatment, or both. Clinical researches are mainly focused on the dominant motor symptoms of PD, but the nonmotor features of PD also need attention. Sexual dysfunctions (SD) are one of the most neglected nonmotor symptoms in PD. SD usually begin after the onset of motor disorders and many patients receiving DA agonists as treatment manifest uncontrollable sexual desire, playing thus a major role in the deterioration of the life's quality of patients and their partners. Research articles were retrieved from PubMed and Google using relevant keywords. Overall, this review emphasize on the sexual disorders widely reported in patients with PD and the types of natural products that are potential future supplementary agents in their control.

show abstract

Late (Complicated) Parkinson's Disease

Horstink

Tolosa

Bonuccelli

et al. 2006

European Handbook of Neurological Management

View full text Add to dashboard Cite

Efficacy and Safety of Fixed-Dose Oral Sildenafil in the Treatment of Sexual Dysfunction in Depressed Patients with Idiopathic Parkinson's Disease

Cited by 70 publications

References 25 publications

Safety and efficacy of sildenafil citrate in the treatment of Parkinson-emergent erectile dysfunction: a double-blind, placebo-controlled, randomized study

Safety and efficacy of sildenafil citrate in the treatment of Parkinson-emergent erectile dysfunction: a double-blind, placebo-controlled, randomized study

Male Sexual Disorders in Patients with Parkinson Disease: Treatment with Natural Remedies

Late (Complicated) Parkinson's Disease

Contact Info

Product

Resources

About